Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.

The Journal of pharmacology and experimental therapeutics - 1 Apr 2007

Vittal Ragini, Zhang Hengmin, Han Meilan K, Moore Bethany B, Horowitz Jeffrey C, Thannickal Victor J

Abstract excerpt

Tissue injury in mammals triggers both inflammatory and repair responses that, in some contexts, results in fibrosis. Fibrosis is characterized by the persistence of activated myofibroblasts, ineffective re-epithelialization, and variable degrees of inflammation within injured tissues. The protein kinase inhibitor (PKI), imatinib mesylate, has been proposed as a potential antifibrotic therapeutic agent. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Bleomycin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bromodeoxyuridine

Share to Caspase 3

Share to Gastrointestinal Stromal Tumors

Share to Indicators and Reagents

Share to Injections, Intraperitoneal

Share to Lung Diseases

Source

Identifiers

PMID: 17218487
DOI: 10.1124/jpet.106.113407

Genes

SMAD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.PMID 17218487Read ↗

Protein kinase inhibitors in the treatment of pulmonary fibrosis.Semantic proximity Read ↗

Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury.Semantic proximity Read ↗

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.Semantic proximity Read ↗

Negative Regulation of Myofibroblast Differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10)Semantic proximity Read ↗

Matrix-driven Myosin II Mediates the Pro-fibrotic Fibroblast Phenotype.Semantic proximity Read ↗

Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-β.Semantic proximity Read ↗

PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.Semantic proximity Read ↗

Mesenchymal cells isolated after acute lung injury manifest an enhanced proliferative phenotype.Semantic proximity Read ↗

Lack of MK2 inhibits myofibroblast formation and exacerbates pulmonary fibrosis.Semantic proximity Read ↗

Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 IsoformsSemantic proximity Read ↗

Epithelial vs myofibroblast differentiation in immortal rat lung cell lines--modulating effects of bleomycin.Semantic proximity Read ↗

Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.